Aptevo Therapeutics is developing novel therapeutics for oncology and hematology. The immune system, including T cells, play an important role in the detection and killing of tumor cells, but is often suppressed by the tumor itself. Using their proprietary modular protein technology platform, ADAPTIR, Aptevo is designing both mono- and bispecific protein therapeutics to redirect T cells to kill tumor cells. Aptevo’s lead candidate, APVO436, is a bispecific candidate that is designed to redirect CD3-expressing T cells to kill CD123-positive tumors for treatment of acute myeloid leukemia. Apetvo has also built their ADAPTIR-FLEX platform, which expands upon ADAPTIR by enabling the design of protein therapeutics with multivalent binding to improve specificity and potency.

<p>Aptevo Therapeutics is developing novel therapeutics for oncology and hematology. The immune system, including T cells, play an important role in the detection and killing of tumor cells, but is often suppressed by the tumor itself. Using their proprietary modular protein technology platform, ADAPTIR, Aptevo is designing both mono- and bispecific protein therapeutics to redirect T cells to kill tumor cells. Aptevo’s lead candidate, APVO436, is a bispecific candidate that is designed to redirect CD3-expressing T cells to kill CD123-positive tumors for treatment of acute myeloid leukemia. Apetvo has also built their ADAPTIR-FLEX platform, which expands upon ADAPTIR by enabling the design of protein therapeutics with multivalent binding to improve specificity and potency.</p>


Aptevo Therapeutics

Founded: 2016
Location: Seattle, WA
Employee range: 50 - 200
Clinical stage: Clin1b
Therapy area: AML/MDS
Drug types: ONC
Lead product: APVO436
Funding: $5M stock Aug 2023; $9.6M stock Mar 2023; $22M stock Mar 2019

Drug notes:

About:

Jobs: